Vendor comparison · 2026
Ipamorelin vendors: 30 compared on COAs and price
OtherAlso known as NNC 26-0161
Evidence tier
Multiple human trials
3 human trials
- Vendors carrying it
- 30
- 28 with a listed price
- Vendors with checkable COAs
- 16
- 17 publish any certificate
- Lots tested
- 29
- 28 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 24 Sept 2026
- oldest 6 Jul 2024
- Laboratories named
- 12
- most often Freedom Diagnostics Testing
- Median label gap
- 4.5%
- 55% of lots within 5% of label
- Median purity
- 99.80%
- 29 of 29 lots at 99% or above
- Lowest price per mg
- $3.90
- peer median $6.20
- Publications located
- 53
- researched since 1998
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
PeptidePlugs has the most checkable Ipamorelin testing in this index: 3 lots assayed by Freedom Diagnostics Testing, the newest on 9 Sept 2026. The lowest listed price is $3.90 per mg at Bench Grade Peptides, against a peer median of $6.20. 30 vendors carrying Ipamorelin are compared below. 16 publish at least one certificate naming a checkable laboratory, 29 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Ipamorelin
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Next Gen PeptidesISO/IEC 17025 | 93.197% | $4.20 (68%) | 2 / 2 | ILS Laboratories | 99.7% | 3.7% | ||
| 2 | PeptidePlugs | 91.394% | $4.00 (65%) | 3 / 3 | Freedom Diagnostics Testing | 99.8% | 9.6% | ||
| 3 | Ascend ScienceISO/IEC 17025 | 90.694% | $4.90 (79%) | 0 | — | — | — | — | |
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 89.498% | $5.00 (81%) | 2 / 2 | ILS Laboratories | 99.7% | 4.2% | ||
| 5 | Bench Grade Peptides | 87.789% | $3.90 (63%) | 3 / 3 | AV Analytics, Freedom Diagnostics Testing | 99.8% | 8.1% | ||
| 6 | One Aminos | 82.489% | $6.00 (97%) | 1 / 1 | United Laboratories | 99.5% | 7.0% | ||
| 7 | Transition Biotech | 80.891% | $4.50 (73%) | 1 / 1 | Kovera Labs | 99.7% | 4.7% | ||
| 8 | Modern AminosISO/IEC 17025COAs need an account | 80.397% | $6.40 (103%) | 2 / 2 | Freedom Diagnostics Testing | 99.9% | 5.9% | ||
| 9 | NeuroLabs Research | 79.891% | $6.50 (105%) | 1 / 1 | Freedom Diagnostics Testing | 99.5% | 6.6% | ||
| 10 | Evo Labs Research | 79.387% | $4.00 (65%) | 0 | — | — | — | — | no reportVisit site |
| 11 | CuroISO/IEC 17025 | 78.497% | $7.90 (127%) | 2 / 2 | BTLabs | 99.8% | 6.2% | ||
| 12 | Simple Peptide | 78.192% | $6.50 (105%) | 2 / 2 | Freedom Diagnostics Testing | 99.9% | 14.4% | ||
| 13 | Prime PeptidesISO/IEC 17025 | 76.396% | $6.00 (97%) | 1 / 1 | Bioviridian Inc. | 99.8% | 4.4% | ||
| 14 | Protide HealthAge-gated COAs | 73.992% | $7.50 (121%) | 0 | — | — | — | — | no reportVisit site |
| 15 | Good Science Bio | 7371% | $4.50 (73%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Licensed Peptides | 71.387% | $6.90 (111%) | 1 / 1 | Vanguard Laboratory | 99.8% | 7.5% | ||
| 17 | Northline LabsISO/IEC 17025 | 7195% | — | 2 / 2 | ILS Laboratories, Horizon Analytical | 99.4% | 1.2% | ||
| 18 | Ascension Peptides | 69.189% | $10.00 (161%) | 3 / 3 | MZ Biolabs | 99.8% | 0.2% | ||
| 19 | Extreme Peptides | 67.980% | $5.36 (87%) | 0 / 1 | Not named | 99.9% | 0.0% | ||
| 20 | BioLongevity Labs | 66.572% | $6.50 (105%) | 0 | — | — | — | — | no reportVisit site |
| 21 | Hydro Research PeptidesISO/IEC 17025 | 65.689% | $15.00 (242%) | 1 / 1 | Janoshik Analytical | 99.9% | 13.0% | ||
| 22 | True Research Labs | 6568% | $5.90 (95%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Eternal Peptides | 64.963% | $5.30 (86%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Koi PeptidesAge-gated COAs | 64.192% | $10.00 (161%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Mile High Compounds | 61.191% | $6.00 (97%) | 0 | — | — | — | — | no reportVisit site |
| 26 | Vial Drop Labs | 59.474% | — | 1 / 1 | KMD Analytical (KMD Group LLC) | 99.9% | 0.2% | ||
| 27 | GenX Peptides | 52.869% | $11.00 (177%) | 0 | — | — | — | — | no reportVisit site |
| 28 | Biotech Peptides | 52.460% | $9.20 (148%) | 0 | — | — | — | — | no reportVisit site |
| 29 | Evolve Peptides | 52.468% | $11.29 (182%) | 0 | — | — | — | — | no reportVisit site |
| 30 | Sports Technology LabsAge-gated COAs | 50.771% | $25.80 (250%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Ipamorelin is on file. All 29 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
29 of 29 lots at 99% or above; median 99.80%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 1 |
| ≥99.5% | 28 |
55% of lots within 5% of the labelled mass; median gap 4.5%.
| Range | lots |
|---|---|
| ≤2% | 7 |
| 2–5% | 9 |
| 5–10% | 7 |
| 10–20% | 6 |
| >20% | 0 |
28 vendors, $3.90 to $25.80; median $6.20.
| Range | vendors |
|---|---|
| $0–$5.00 | 7 |
| $5.00–$10.00 | 15 |
| $10.00–$15.00 | 4 |
| $15.00–$20.00 | 1 |
| $20.00–$25.00 | 0 |
| $25.00–$30.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 9 | 5 | 31% | Public lookup |
| ILS LaboratoriesUS | 5 | 3 | 17% | Public lookup |
| MZ BiolabsUS | 3 | 1 | 10% | No public lookup found |
| AV Analytics | 2 | 1 | 7% | No public lookup found |
| BTLabs | 2 | 1 | 7% | No public lookup found |
| Bioviridian Inc.US | 1 | 1 | 3% | Public lookup |
| Horizon Analytical | 1 | 1 | 3% | No public lookup found |
| Janoshik AnalyticalCZ | 1 | 1 | 3% | Public lookup |
| KMD Analytical (KMD Group LLC)US | 1 | 1 | 3% | Public lookup |
| Kovera Labs | 1 | 1 | 3% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 3% | Public lookup |
| Vanguard LaboratoryUS | 1 | 1 | 3% | No public lookup found |
1 further record namesno checkable laboratory (a placeholder, a signature line or the vendor’s own name). It is listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1998 — 28 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
53 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.8% across 29 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.16 pts purity across lots, mean label deviation 5.8%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
30 of 30 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
28 of 29 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Ipamorelin?
A synthetic pentapeptide that acts as a growth hormone secretagogue in published preclinical work. Supplied as a lyophilised powder.
Studied in published research for growth-hormone release, recovery and body composition.
Regulatory status
Labeled by vendors for laboratory research use only. Not an approved medicine.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
The published literature is mainly preclinical, with a small number of early-phase human studies that were not carried forward to approval. No approved product exists.
- Ipamorelin, the first selective growth hormone secretagogue — European journal of endocrinology (1998)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1998).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine (2026)
Peer-reviewed article indexed in PubMed, published in The American journal of sports medicine (2026).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Resear (1999)
Peer-reviewed article indexed in PubMed, published in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1999).
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism — Physiology & behavior (2024)
Peer-reviewed article indexed in PubMed, published in Physiology & behavior (2024).
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus — Animal reproduction science (2024)
Peer-reviewed article indexed in PubMed, published in Animal reproduction science (2024).
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Pharmaceutical research (1999)
Peer-reviewed article indexed in PubMed, published in Pharmaceutical research (1999).
Indexed studies3 human-evidence of 3
- Early-phase human work on ipamorelin — Human — controlled trial
A small early-phase human literature exists. The development programme was not carried forward to approval, and the listed work does not establish a durable clinical effect.
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — Human — controlled trial, 2014
Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074). The design was a multicenter, double-blind, placebo-con…
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Human — controlled trial, 1999
To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. The PK parameters showed dose-proportionality, with a short terminal …
Evidence digest
What the research on ipamorelin actually shows
Ipamorelin has a small early-phase human literature that was not carried forward to approval. Development programmes are abandoned for many reasons — commercial, strategic and scientific — and the published record does not establish a durable clinical effect. A discontinued programme is not evidence of efficacy, and it is not evidence of harm either; it is an absence of conclusion.
4 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.